Home>>Signaling Pathways>> Angiogenesis>>TRX-818 (sodium salt)

TRX-818 (sodium salt)

Catalog No.GC48210

An anticancer compound

Products are for research use only. Not for human use. We do not sell to patients.

TRX-818 (sodium salt) Chemical Structure

Cas No.: 1256037-62-3

Size Price Stock Qty
1 mg
$61.00
In stock
5 mg
$231.00
In stock
10 mg
$432.00
In stock
25 mg
$926.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

TRX-818 is an anticancer compound.1,2 It inhibits vasculogenic mimicry network formation in C8161 and SK-MEL-28 melanoma cells when used at concentrations ranging from less than or equal to 5 to 10 nM. 1 TRX-818 (10 nM) decreases pro-Nodal protein levels and Smad2 phosphorylation in C8161 cells. It reduces tumor volume with a minimum effective dose (MED) value of 50 mg/kg and decreases the number of vasculogenic mimicry channels in tumors when administered at a dose of 100 mg/kg in an HCT116 colon cancer mouse xenograft model. TRX-818 (7.5, 15, and 30 mg/kg) reduces tumor growth in a Hep3B mouse xenograft model in a dose-dependent manner.2

1.Chu, Y.-W., and Chien, D.-S.Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry(2016) 2.Chou, L.-C., Tsai, M.-T., Hsu, M.-H., et al.Design, synthesis, and preclinical evaluation of new 5,6- (or 6,7-) disubstituted-2-(fluorophenyl)quinolin-4-one derivatives as potent antitumor agentsJ. Med. Chem.53(22)8047-8058(2010)

Reviews

Review for TRX-818 (sodium salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TRX-818 (sodium salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.